Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

被引：4
|
作者：
Quintela-Fandino, Miguel
Apala, Juan V.
Salgado, Alfonso Cortes
Mouron, Silvana Andrea
Guerra, Juan Antonio
Cortes, Mana Gion
Morente, Manuel
Manso, Luis
机构：
[1] CNIO Spanish Natl Canc Res Ctr, Madrid, Spain
[2] CNIO, Madrid, Spain
[3] Hosp Ramon & Cajal, Madrid, Spain
[4] Spanish Natl Canc Res CNIO, Breast Canc Clin Res Unit, Madrid, Spain
[5] Hosp Fuenlabrada, Madrid, Spain
[6] Hosp 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2552
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A prospective randomized phase II study to identify predictive biomarkers and mechanisms of resistance in patients with HER2-negative metastatic breast cancer treated with the combination of bevacizumab and paclitaxel
    Foukakis, T.
    Hartman, J.
    Stone-Elander, S.
    Jacobsson, H.
    Bergh, J.
    CANCER RESEARCH, 2013, 73
  • [42] Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC)
    Carmeliet, P.
    Pallaud, C.
    Deurloo, R. J.
    Bubuteishvili-Pacaud, L.
    Henschel, V.
    Dent, R.
    Bell, R.
    Mackey, J.
    Scherer, S. J.
    Cameron, D.
    CANCER RESEARCH, 2012, 72
  • [43] Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI)
    Yardley, Denise Aysel
    Bosserman, Linda D.
    Peacock, Nancy Walker
    Favret, Anne
    Morgan, Susan Kay
    Priego, Victor M.
    Bass, J. David
    Griner, Paula L.
    Burris, Howard A.
    Hainsworth, John D.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
    Marme, Frederik
    Gerber, Bernd
    Schmidt, Marcus
    Moebus, Volker Jochen
    Foerster, Frank Gerhard
    Grischke, Eva-Maria
    Beckmann, Matthias W.
    Strumberg, Dirk
    Solomayer, Erich
    Klare, Peter
    Windemuth-Kieselbach, Christiane
    Schneeweiss, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
    Saji, Shigehira
    Taira, Naruto
    Kitada, Masahiro
    Takano, Toshimi
    Takada, Masahiro
    Ohtake, Tohru
    Toyama, Tatsuya
    Kikawa, Yuichiro
    Hasegawa, Yoshie
    Fujisawa, Tomomi
    Kashiwaba, Masahiro
    Ishida, Takanori
    Nakamura, Rikiya
    Yamamoto, Yutaka
    Toh, Uhi
    Iwata, Hiroji
    Masuda, Norikazu
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    LANCET ONCOLOGY, 2022, 23 (05): : 636 - 649
  • [46] SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
    Christoph Rochlitz
    Martin Bigler
    Roger von Moos
    Jürg Bernhard
    Klazien Matter-Walstra
    Andreas Wicki
    Khalil Zaman
    Sandro Anchisi
    Marc Küng
    Kyung-Jae Na
    Daniela Bärtschi
    Markus Borner
    Tamara Rordorf
    Daniel Rauch
    Andreas Müller
    Thomas Ruhstaller
    Marcus Vetter
    Andreas Trojan
    Ursula Hasler-Strub
    Richard Cathomas
    Ralph Winterhalder
    BMC Cancer, 16
  • [47] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [48] SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
    Rochlitz, Christoph
    Bigler, Martin
    von Moos, Roger
    Bernhard, Jurg
    Matter-Walstra, Klazien
    Wicki, Andreas
    Zaman, Khalil
    Anchisi, Sandro
    Kung, Marc
    Na, Kyung-Jae
    Bartschi, Daniela
    Borner, Markus
    Rordorf, Tamara
    Rauch, Daniel
    Mueller, Andreas
    Ruhstaller, Thomas
    Vetter, Marcus
    Trojans, Andreas
    Hasler-Strub, Ursula
    Cathomas, Richard
    Winterhalder, Ralph
    BMC CANCER, 2016, 16
  • [49] MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer
    Miles, David
    Faoro, Leonardo
    Wang, Yan V.
    O'Shaughnerary, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials
    Wei, Jinli
    Luo, Yulin
    Fu, Deyuan
    ONCOTARGETS AND THERAPY, 2018, 11 : 9049 - 9059
12345